What Intelligent OMICS does

Intelligent OMICS Limited (Intellomx) is a UK-based biotechnology company founded in 2009 that applies proprietary artificial intelligence and machine learning to accelerate drug discovery. Its core platform interrogates transcriptomic, genomic, and proteomic (OMICS) data de novo using artificial neural network algorithms — explicitly not LLM-based literature mining — to uncover causal disease drivers, patient biology, and toxicity risk. The proprietary I3 algorithm, developed over 15 years and validated across 50+ case studies (approximately 50% oncology), evaluates up to 50 million models per hour and reportedly identifies drug targets in 5–10 weeks versus the industry-standard 5–10 years. The product suite extends from Pathway Discovery and Digital Twin (off-target testing) to Companion Diagnostics, the POSitive panel-optimization service, and the recently launched Intellomx Pilot swarm-based AI platform.

The company operates a B2B enterprise sales motion targeting pharmaceutical companies, biotechnology firms, and academic research institutions through direct confidential engagement and strategic partnerships — most notably with Johnson & Johnson and Janssen Research & Development, facilitated by Johnson & Johnson Innovation and JLABS. Named commercial customers include Servier Pharmaceuticals and Johnson & Johnson/Janssen (lung cancer and haematological cancers collaborations). Distribution is direct with no resellers; pricing is not publicly disclosed. The company employs 1–10 people across UK locations in Barnham (headquarters), Cambridge, and Nottingham, with commercial presence in Canada. It is privately held by founders, directors, and a small group of private/public investors (Lachesis, NTU, Braveheart, Mobius) with no disclosed institutional venture funding to date.

Name

Intelligent OMICS

Legal name

Intelligent OMICS Limited

Website

https://intellomx.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Intelligent OMICS is a UK-based AI/ML biotechnology company that uses its proprietary I3 artificial neural network platform to interrogate OMICS data de novo for drug target discovery, companion diagnostics, and panel optimization, serving pharmaceutical companies (notably Johnson & Johnson/Janssen and Servier), biotech firms, and research institutions via direct enterprise sales.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Computer Integrated Systems Design (7373), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• AI drug discovery
• OMICS data analysis
• Target identification
• Companion diagnostics
• Biomarker discovery

Headquarters

HQ city

Nottingham

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Intelligent OMICS (Intellomx) sells an AI/ML-powered drug discovery platform built on its proprietary I3 algorithm that interrogates OMICS data (transcriptomic, genomic, proteomic, metabolomic) de novo to uncover causal disease drivers and identify novel drug targets, biomarkers, and companion diagnostics. The platform delivers services including pathway discovery, digital twin off-target testing, novel drug discovery, biomarker panel optimization (POSitive), and the Intellomx Pilot swarm-based AI for rapid drug candidate identification.

Product overview

Intelligent OMICS (Intellomx) offers a unified AI-powered drug discovery platform centered on its proprietary I3 algorithm technology. The core Intellomx Platform uses artificial neural networks to interrogate OMICS data de novo, while specialized modules address specific workflow needs: Pathway Discovery and Novel Drug Discovery for target identification; Digital Twin for off-target effect testing; Intuitive Intelligence for complex data analysis; POSitive for panel optimization; and Driver/Miner/Distiller/Cloud for specialized analytical functions. The recently launched Intellomx Pilot extends the platform with swarm-based AI for accelerated drug candidate identification.

Differentiator

Problem solved

Functional benefit

Brands

• I3: Proprietary AI/ML algorithm that compares up to 50 million models per hour to identify drug targets matched to modulating NCE or existing drugs.
• Intellomx Pilot
• Digital Twin
• POSitive
• Intellomx I3 Discovery Program

Quantifiable outcome

• Drug target identification time reduced from 5-10 years to 5-10 weeks using I3 algorithm comparing 50 million models per hour
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Johnson & JohnsoncoreStrategic or Co-development Partner · 25 June 2025Follow-on target discovery collaboration with Johnson & Johnson to identify and evaluate novel biological targets for the treatment of lung cancer. The collaboration extends previous work in target discovery.
• Janssen Research & Development, LLC (Janssen)coreStrategic or Co-development Partner · 1 September 2023Target discovery collaboration with Janssen Pharmaceutical Companies of Johnson & Johnson to evaluate novel biological targets for the treatment of haematological cancers. Agreement facilitated by Johnson & Johnson Innovation.
• Johnson & Johnson Innovation – JLABScoreStrategic or Co-development Partner · 10 August 2023Joined Johnson & Johnson Innovation – JLABS, a premier life science incubator program. JLABS provides entrepreneurs with lab space, resources, and support needed to bring breakthrough healthcare solutions to patients globally.
• Medicines Discovery CatapultminorStrategic or Co-development PartnerCollaboration referenced in OBN CONNECT Magazine Autumn 2021 article regarding lung cancer assets and wider implications of AI application for global drug discovery.
• ArctorisminorStrategic or Co-development PartnerCollaboration mentioned in OBN CONNECT Magazine article about Biology 2.0, combining machine-learning, robotics and biology to deliver drug discovery of tomorrow.

Recent moves5 records

Expansion highlights5 records

Direct peers

• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML to identify targets and advance programs. Comparable to Intellomx as a fellow AI-for-drug-discovery platform selling target identification and pipeline assets to pharma.
• Exscientia: AI-driven precision medicine company focused on small-molecule drug discovery using its own platforms. Direct comparable to Intellomx in selling AI drug-discovery collaborations to large pharma, with disclosed partnerships across multiple therapeutic areas.
• Insitro: ML-enabled drug discovery platform combining high-throughput biology with predictive models to identify targets and therapeutics. Comparable to Intellomx as a venture-backed AI drug-discovery peer pursuing pharma partnerships.
• BenevolentAI: AI drug-discovery company using knowledge graphs and ML to identify novel targets and indications. Intellomx explicitly differentiates against BenevolentAI-style literature-mining approaches, making it a close adjacent competitor in pharma-facing AI discovery.
• Schrödinger: Computational chemistry and ML platform offering physics-based drug discovery software and services to pharma. Comparable to Intellomx in selling computational drug-discovery capabilities into pharma R&D workflows.
• Isomorphic Labs: Alphabet-owned AI drug-discovery company applying deep learning to structure-based drug design. Direct comparable as a high-profile, well-capitalized AI platform selling pharma partnerships in target identification and molecular design.
• Atomwise: AI small-molecule drug discovery company using convolutional neural networks for hit identification. Comparable to Intellomx as an AI-discovery vendor that signs multi-program pharma collaborations across therapeutic areas.

Emerging players

• Owkin: AI biotech combining federated learning on patient data with OMICS to accelerate drug discovery and development. Comparable to Intellomx in using multi-omics data and ML for target and biomarker discovery with pharma partners.
• Lantern Pharma: AI-driven oncology drug developer using its RADR platform to identify responder populations and repurpose compounds. Comparable to Intellomx in applying ML to OMICS data for biomarker-driven drug development and companion diagnostics.
• Arctoris: Robotics- and ML-enabled drug discovery CRO combining automated wet-lab biology with computational analysis. Direct overlap with Intellomx given their publicly disclosed collaboration, both serve pharma with biology-plus-ML discovery services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/intelligent-omics-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intelligent OMICS